Tazverik gaining momentum

By Brian Buntz | July 21, 2021

TAZVERIK Epizyme FDA has approved TAZVERIK from Epizyme for multiple indications.

The first-in-class EZH2 inhibitor is now indicated for adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.

The drug is also indicated for adults with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. Finally, the agency has approved Tazverik’s use for patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.

Filed Under: Oncology
Tagged With: Epizyme, EZH2 inhibitor, follicular lymphoma, refractory follicular lymphoma, relapsed follicular lymphoma, TAZVERIK

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.